Hims & Hers: The Growth Stopped, the Multiple Did Not

The Setup

Hims & Hers sits at the intersection of two of the most exciting themes on the market: digital health and GLP-1 weight loss. The shares have been a momentum favorite, rising roughly 45% in the past month and breaking back above $30 this week on news that its Juniper platform opened pre-orders for Novo Nordisk's oral Wegovy in the United Kingdom. Retail traders are watching for a breakout. The market is treating Hims as a company whose growth is accelerating.

This is not a piece arguing that Hims is a bad business or a fraud. It is neither. It has more than 2.6 million subscribers, a recurring revenue model, real partnerships with the two largest names in obesity care, and it generates free cash flow. Those are real strengths and they deserve a fair hearing. This is a narrower argument: the price reflects a growth rate the company produced last year and is no longer producing this year, and the gap between the rally and the most recent quarter is wide enough to matter.

The cleanest way to see the gap is to set the stock chart beside the income statement. The chart shows a company being repriced upward on optimism about what comes next. The income statement shows revenue growth that has collapsed from 59% in 2025 to 4% in the first quarter of 2026, margins moving the wrong way, and a swing from profit to loss. Both are real. The question is which one the price reflects.

The Story the Price Is Telling

The bull case is genuinely strong and it deserves to be stated in full before the numbers complicate it. Hims built a subscription telehealth platform with real scale: full-year 2025 revenue of about $2.35 billion, up 59%, with net income of $128 million and adjusted EBITDA of $318 million. That is product-market fit at a level very few digital health companies ever reach, and the recurring nature of the subscriptions is why the market assigns it a technology-style multiple rather than a healthcare one.

The forward story is built on three pillars. First, branded GLP-1 distribution: after partnering with Novo Nordisk (NVO) and Eli Lilly (LLY), Hims fulfilled more than 125,000 Wegovy shipments within six weeks and told investors it is on track to add more than 100,000 new weight loss subscribers per month. Second, international expansion: the Eucalyptus acquisition closed early and pushed rest-of-world revenue from $7.3 million a year ago to $78.2 million last quarter, a genuine new growth vector. Third, optionality in peptides, which is the piece doing most of the work in the recent rally and which gets its own section below.

Management raised full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion and guided second-quarter revenue to $680 million to $700 million, above where the Street sat. If you stop reading there, Hims looks like a scaled, profitable platform with multiple new engines just starting to turn. That is the story the price is built on. The rest of this article is what the most recent quarter actually reported.

The Quarter Underneath the Rally

Hims reported first-quarter 2026 results on May 11, and the headline numbers did not match the momentum. Revenue came in at $608.1 million, up only 4% from $586 million a year earlier, and it missed the analyst estimate near $617 million. For a company that grew 59% the year before and carries a growth multiple, a 4% quarter that misses is not a small detail. It is the detail.

Profitability moved the wrong way across the board. Gross margin fell to 65% from 73% a year earlier. Adjusted EBITDA dropped to $44.3 million from $91.1 million, cutting the margin to about 7%. Most strikingly, the company swung to a net loss of $92.1 million, or about $0.41 per share, reversing $49.5 million of net income in the same quarter a year earlier.

Underneath the totals, the mix is deteriorating in ways the headline subscriber count hides. The subscriber base grew 9% to nearly 2.6 million, but monthly revenue per average subscriber fell to $80 from $85, so each subscriber is worth less. United States revenue, still the overwhelming majority of the business, actually declined 8% to $529.9 million. The growth that remains is being carried by a small international base off a tiny prior-year number. The core domestic engine, the one the valuation is built on, shrank.

The Compounded-GLP-1 Problem

The deceleration is not an accident, and understanding why it happened is the key to the whole thesis. A large part of 2025's explosive growth came from compounded semaglutide, the lower-cost version of the active ingredient in Wegovy and Ozempic that Hims was able to sell while the branded drugs were in shortage. That business carried high margins and scaled fast. When the shortages resolved, Hims agreed in March to stop promoting compounded GLP-1s and to distribute Novo's branded products instead.

That decision was probably necessary, but it is expensive. Branded distribution carries far lower margins than compounded products Hims made itself, which is exactly why gross margin compressed eight points in a single year. The transition also cost $33.5 million in restructuring charges, a $15 million legal settlement, and inventory write-downs. The high-margin growth driver of 2025 is being swapped, by necessity, for a lower-margin one in 2026.

This is the uncomfortable core of the situation. The single product that drove the hypergrowth the multiple still reflects is the same product the company just walked away from. The replacement engines, branded GLP-1 distribution and international expansion, are real and growing, but they are structurally less profitable and have not yet scaled to replace what was lost. That is why a business everyone calls hypergrowth printed a 4% quarter. The growth did not pause. It changed character.

The Peptide Bet

If the current business explains the deceleration, the recent rally is explained by something that has not happened yet. Next month, the Pharmacy Compounding Advisory Committee is scheduled to meet to decide whether a set of peptides should be added to the so-called 503A bulk substances list, a move that would let compounders, Hims among them, produce them. Analysts at Leerink have framed a favorable outcome as a potential growth catalyst beyond 2027.

The number being attached to that possibility is large. One analyst has suggested Hims could generate between $10 billion and $19 billion in annual peptide-related revenue by 2030 if it captures just 4% to 5% of the combined peptide market. To put that in perspective, the entire company is guiding to $2.8 billion to $3.0 billion in total revenue this year. The peptide figure being floated is multiples of the whole business, built on a regulatory decision that has not been made, a market share that has not been won, and a product line that does not yet exist at scale.

That is the structure of the rally. The stock is being repriced upward on the most optimistic reading of an event that is still in front of the company, while the reported results show the existing engines slowing. Compounded GLP-1s were a similar story once: a regulatory window that opened, drove enormous growth, and then closed. Pricing the next regulatory window as though it is already open, and already won, is exactly the pattern this kind of analysis exists to flag.

What the Wealth Engine Scores Say

Before the valuation verdict, here is what the Wealth Engine Pro platform's systematic scoring shows for Hims right now.

The platform rates Hims as Weak with a Bearish outlook and a blended fair value of $7.50. That fair value is aggressive, and it is worth being transparent about why: the models (discounted cash flow, peer comparison, earnings power) are reacting to a business that just decelerated to 4% growth, compressed margins, and posted a loss, and they assign no credit for speculative future catalysts. The number to anchor on is not the precise $7.50. It is the direction and the size of the gap. Every model the platform runs lands on the same verdict: Expensive.

These scores are systematic. They evaluate companies based on reported financials, balance sheet quality, moat characteristics, and valuation models. They measure what a company is today, not what it might become. That is by design: the scoring system is built to keep emotion and forward speculation out of the numbers, which is precisely the speculation carrying the current price.

In this case, the editorial thesis and the platform scores point in the same direction. The article argues the price reflects a growth rate the company is no longer producing, and the systematic data, which cannot price a peptide approval that has not happened, reads Weak, Expensive, and Bearish for the same underlying reason. When both the quantitative model and the qualitative analysis flag the same gap between price and substance, that convergence is worth paying attention to. Research Hims yourself on the platform and decide which signal matters more for your situation.

The Valuation Verdict

Strip away the labels and the valuation question is simple. Hims carries a roughly $7 billion market cap and trades at more than 50 times forward earnings and roughly 2.3 times this year's revenue guidance, on a business that just grew 4% with compressing margins. A multiple like that is the market paying in advance for re-acceleration. The most recent quarter is evidence of deceleration.

There is a respectable bull-case math, and it deserves to be stated fairly. One independent model that sets a $55 price target gets there by assuming a 12% revenue compound growth rate from 2025 all the way through 2035 and a net margin near 9%. That is a coherent path. It is also a decade of steady double-digit growth and a structural margin improvement that the company has not demonstrated, layered on top of a year in which growth fell to 4% and margins fell eight points. The bull case is not impossible. It is a long sequence of things that all have to go right.

That is the disconnect the data keeps surfacing. The buyer near $30 is not paying for a profitable telehealth platform growing at 4%. The buyer is paying for the re-acceleration, the branded GLP-1 ramp hitting margin targets, the international base compounding, and the peptide market opening and being captured, all arriving more or less on schedule. Each of those is a real possibility. The price treats the whole set as close to settled. It is the same pattern examined in The SaaS Reckoning: a recurring-revenue business earning a technology multiple that the underlying numbers no longer support.

What Could Go Wrong

Every avoid thesis owes the other side an honest hearing, and this one has a stronger bull case than most. A buyer at today's price is making several reasonable bets.

The loss was largely a one-time reset. Despite the GAAP loss, Hims generated about $89 million in operating cash flow and $53 million in free cash flow in the quarter. Much of the net loss came from restructuring charges and write-downs tied to the GLP-1 transition, not from the core business burning cash. If the transition is a one-time hit, the margin profile could recover as branded distribution scales.

The new engines are real and early. 125,000 Wegovy shipments in six weeks and a target of 100,000 new weight loss subscribers a month are not trivial, and the international expansion is growing from almost nothing. If those compound for a few quarters, the 4% print looks like a transition trough rather than a new normal.

The peptide catalyst could actually land. If the advisory committee adds peptides to the 503A list and Hims executes, a genuine new high-margin product line opens up. The optionality the bears dismiss is not zero. It is simply unpriced risk dressed as near-certain reward.

Short interest cuts both ways. Roughly 34% of the float is sold short. That is the bear case in one number, but it is also a loaded spring: any positive surprise, an upbeat guide, a favorable FDA decision, a strong subscriber month, can force short covering and drive the stock sharply higher regardless of valuation. An avoid thesis on a heavily shorted momentum name can be right on the fundamentals and still painful in the short run.

The thesis breaks if the branded and international engines re-accelerate growth back toward the rate the multiple implies, with margins recovering as the transition costs roll off. In that world the stock grows into its price. What the avoid thesis argues is not that this is impossible. It is that the current price already assumes it, leaving little reward if it works and meaningful downside if the re-acceleration is slow, the margins stay compressed, or the peptide bet does not pay. It is the same asymmetry examined in The Quantum Computing Bubble and across the GLP-1 names in the Eli Lilly versus Novo Nordisk battle: a real opportunity, priced as though the hard part is already done.

The Bottom Line

Hims & Hers is not a bad company. It has millions of loyal subscribers, real partnerships, positive cash flow, and credible new growth vectors. If the branded and international engines re-accelerate and the peptide bet pays, the bulls will be right and this article will age poorly. That outcome is possible. It is simply not what the current price represents, because the current price represents that outcome as already in hand.

The most recent quarter showed revenue growth of 4% against 59% a year earlier, gross margin down to 65% from 73%, adjusted EBITDA cut in half, a $92 million net loss, and falling revenue per subscriber. The number carrying the rally, a $10 billion to $19 billion peptide opportunity by 2030, rests on a regulatory decision that has not been made. The platform's systematic scoring reads Weak, Bearish, and Expensive. Every independent angle lands in the same place.

That is the entire philosophy here. Wealth Engine Pro evaluates companies on what they are, not on what the most exciting version of the story hopes they will become. The narrative says Hims is a hypergrowth platform with a peptide windfall ahead. The data says it is a profitable but decelerating telehealth company in the middle of a margin-compressing transition, priced as though the next growth wave has already arrived. When the gap between those two pictures is this wide, the data is the part worth trusting until the results prove otherwise.